SCHEMBL7594615

SCHEMBL7594615

CC(N)c1ccc(C(=O)O)cc1C(C)N

nearest known ligand 0.56

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
GRM1 Q13255 2/20 0.56
TDP1 Q9NUW8 2/20 0.56
KMT2A Q03164 2/20 0.56
MEN1 O00255 1/20 0.56
CYP1A2 P05177 1/20 0.56
ACE2 Q9BYF1 4/20 0.49
TSHR P16473 2/20 0.42
TP53 P04637 1/20 0.42
CA12 O43570 2/20 0.42
CA1 P00915 2/20 0.42
CA2 P00918 2/20 0.42
CA4 P22748 2/20 0.42
CA6 P23280 2/20 0.42
CA7 P43166 2/20 0.42
CA9 Q16790 2/20 0.42
CA14 Q9ULX7 2/20 0.42
KDM4E B2RXH2 1/20 0.42
POLB P06746 1/20 0.42
GAA P10253 1/20 0.42
MAPT P10636 1/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL29242326 0.85 GRM1 (0.72) GRM1TDP1KMT2AMEN1CYP1A2
Hydrochloric Acid SCHEMBL12499457 0.83 GRM1 (0.70) GRM1TDP1KMT2AMEN1CYP1A2
SCHEMBL31733483 0.83 GRM1 (0.51) GRM1TDP1KMT2AMEN1CYP1A2
SCHEMBL2438341 0.83 GRM1 (0.51) GRM1TDP1KMT2AMEN1CYP1A2
SCHEMBL9185164 0.83 LMNA (0.56) GRM1TDP1KMT2AMEN1CYP1A2
SCHEMBL12584011 0.83 GRM1 (0.51) GRM1TDP1KMT2AMEN1CYP1A2
SCHEMBL12583708 0.83 LMNA (0.56) GRM1TDP1KMT2AMEN1CYP1A2
SCHEMBL3649293 0.83 GRM1 (0.51) GRM1TDP1KMT2AMEN1CYP1A2
Hydrochloric Acid SCHEMBL986200 0.82 LMNA (0.55) GRM1TDP1KMT2AMEN1CYP1A2
Hydrochloric Acid SCHEMBL986198 0.82 LMNA (0.55) GRM1TDP1KMT2AMEN1CYP1A2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20020082280-A1 Method of inhibiting neoplastic cells with benzimidazole derivatives OSI PHARMACEUTICALS, INC. 2002-06-27 US disclosed
US-6348032-B1 POTENT COMPOUNDS THAT INDUCE APOPTOSIS IN NEOPLASTIC CELLS (BUT NOT SUBSTANTIALLY IN NORMAL CELLS), WITHOUT SUBSTANTIALLY INHIBITING PGE-2. CELL PATHWAYS, INC. 2002-02-19 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20020082280-A1 Method of inhibiting neoplastic cells with benzimidazole derivatives MKI67, CCNI, TMBIM6 GRM1 4732/4885TDP1 3757/4885KMT2A 1590/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.